WOONSOCKET, R.I., July 30 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has launched a new website with a fresh new look and updated information about discovery technology platforms and lead drug candidates. It also provides information to answer investors' most common questions.
"The new website is designed to inform our shareholders, scientists and the public about the Company's proprietary therapeutic pipeline which could fill critical unmet medical needs," stated W. Gerald Newmin, Chairman and CEO of MultiCell.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools to address unmet medical needs for treatment of neurological disorders, hepatic disease and cancer.
MultiCell's therapeutic development platform relies on patented techniques to: (i) isolate, characterize and differentiate stem cells from the human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin treatment, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.
MultiCell's drug candidates are in various stages of discovery optimization, and preclinical and clinical development:
- MCT-125 is a Phase 2 therapeutic candidate for treatment of fatigue in MS patients, which has demonstrated efficacy in a 138-patient Phase IIa clinical trial.
- MCT-465 is